A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

This study has been completed.

Study NCT00055471 Information provided by AstraZeneca

First Received: March 3, 2003 Last Updated: October 20, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given